Immortal Dragons Backs 3D Biofabrication to Solve Organ Failure

SINGAPORE

For decades, the medical establishment has operated on a reactive model: treating disease after it strikes rather than preventing it from developing in the first place. But a new paradigm is shifting the focus from sick-care to extending healthspan keeping people healthy before problems emerge.

On a recent episode of Inside Precision Medicine’s Behind the Breakthroughs podcast, host Jonathan Grinstein sat down with Boyang Wang, the founder of a Singapore longevity fund Immortal Dragons, to discuss why the future of human longevity isnt just about living longer its about replacing worn-out biology before disease takes hold.

The Catalyst: 3D Biofabrication

The most evocative segment of the discussion centered on 3D biofabrication, a field that has moved rapidly from science fiction to laboratory reality.

Unlike traditional 3D printing, biofabrication uses bio-inks living cells combined with biocompatible materials. The technology targets critical unmet needs like vascular grafts, a $12 billion market where current synthetic solutions fail up to 65% of the time. Recent breakthroughs have produced tissue-engineered blood vessels that show zero thrombosis, proper cell integration, and tissue incorporation in large animal studies dramatically outperforming conventional synthetics.

Immortal Dragons backing of Frontier Bio is a strategic bet on replacement technology as the solution to organ failure the leading cause of death for those over 65. The field is maturing fast: in 2024, United Therapeutics received FDA clearance for the first human trial of a bioengineered organ. While whole organs remain on the horizon, functional blood vessels prove biofabrication is moving from lab to clinic.

The Four Pillars of the Future

Boyangs entry into the longevity space wasnt born in a clinic, but from the bold pivot of a technologist and entrepreneur. Coming from tech, he understood transformative breakthroughs require patient capital.

This realization led to the birth of Immortal Dragons, a purpose-driven longevity fund built on long-term conviction, pushing longevity boundaries through capital, philanthropy and evangelism.

According to Boyang, solving the aging puzzle requires more than just a clever lab discovery. He outlined a holistic framework consisting of four essential pillars:

1. Science: The fundamental understanding of why we age at a cellular level.
2. Capital: Funding models that prioritize long-term health over short-term exits.
3. Policy: Modernizing regulatory frameworks and clinical trial designs to account for preventative therapies.
4. Ideology: Changing the social narrative from aging is inevitable to aging is a manageable biological process.

A Coordinated Leap Forward

The discussion highlighted a growing effort to move longevity research into the mainstream of biomedical science. While the ability to significantly extend the human healthspan remains a subject of intense scientific debate, the field is increasingly characterized by coordinated, interdisciplinary research. The primary objective now is to establish a rigorous framework for evaluating these interventions, requiring a careful synchronization of long-term investment and regulatory oversight to determine what is biologically possible.

About Immortal Dragons

Immortal Dragons is a purpose-driven longevity fund headquartered in Singapore. The fund invests in cutting-edge, high-impact technologies and currently supports more than 15 portfolio companies. Beyond conventional investments, the fund advances longevity advocacy through book translation and publishing, translation of longevity leaders’ talks, hosting a leading Chinese-language longevity podcast, and providing sponsorships and grants to longevity initiatives and conferences.

For Press Inquiries

Boyang Wang

Founder, Immortal Dragons

[email protected]

You May Also Be Interested In

• FDA accepts Teva's drug application for Tourette syndrome therapy in children
• Ameritas announces officer action
• Althea Copper Corp. To List its Common Shares on The Canadian Securities Exchange